Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Inclusion Criteria:

• Histologically confirmed AML, B-ALL or MDS. Subjects must have exhausted allavailable standard therapies or be deemed ineligible for potential availabletherapies.

• Evidence of ≥5% bone marrow or blood blasts (acute leukemia) or ≥5% bone marrow orblood myeloblasts (MDS) to allow for assessment of drug activity.

• Evidence of CD123 expression from a local laboratory.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

Exclusion Criteria:

• Known central nervous system (CNS) metastases and/or carcinomatous meningitis.

• Clinically significant cardiac disease including congestive heart failure > New YorkHeart Association (NYHA) Class II), evidence for coronary artery disease (eg,unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6months or myocardial infarction within the past 6 months before first dose.